StockData
Cardiol Therapeutics Inc. logo

Cardiol Therapeutics Inc. (CRDL) stock

CRDLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Số liệu tài chính tới năm tài chính 2025, năm kết thúc ngày Dec 31, 2025Last filing: 40-F on Mar 31, 2026Score 5/30
$0.86−0.02 (-2.28%)

Close on Nov 20, 2026Market cap $86.48MP/E –Yield –

Cardiol Therapeutics r&d expenses

Research and development expenses are spending on new products and technology.

For fiscal 2025 it was C$14.02M, up 0.0% from the year before. The highest annual figure on record is C$18.96M in fiscal 2022.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025C$14.02M+0.0%
FY2024Dec 31, 2024C$14.01M-1.5%
FY2023Dec 31, 2023C$14.22M-25.0%
FY2022Dec 31, 2022C$18.96M+74.4%
FY2021Dec 31, 2021C$10.87M+2.5%
FY2020Dec 31, 2020C$10.60M–

More Cardiol Therapeutics figures

See a number that looks wrong?